|
Patent landscape, scope, and claims: |
Analysis of U.S. Drug Patent 11,786,455: Scope, Claims, and Landscape
U.S. Patent 11,786,455, granted on October 17, 2023, to Regeneron Pharmaceuticals, Inc., claims novel antibodies and methods for treating or preventing fibrotic diseases. The patent encompasses specific immunoglobulin G1 (IgG1) antibodies, including REGN5093 and REGN5093-1, that target a particular epitope on the protein TGF-β1. Fibrotic diseases, characterized by excessive deposition of extracellular matrix, represent a significant unmet medical need across multiple organ systems. This analysis details the patent's scope, the precise language of its claims, and the broader patent landscape surrounding TGF-β1 inhibition and fibrotic disease therapeutics.
What is the Scope of U.S. Patent 11,786,455?
The patent's scope is defined by its claims, which delineate the intellectual property protection granted. U.S. Patent 11,786,455 broadly covers:
- Specific Antibodies: The patent claims specific antibodies, including REGN5093 and REGN5093-1, which are characterized by their binding affinity and interaction with TGF-β1. These antibodies are designed to neutralize the biological activity of TGF-β1.
- Epitope Binding: A core aspect of the patent is the claimed binding to a specific epitope on TGF-β1. This epitope is identified as a region on the TGF-β1 protein that, when bound by the antibody, inhibits its downstream signaling pathways implicated in fibrosis.
- Methods of Treatment: The patent claims methods of treating or preventing fibrotic diseases. This includes administering the claimed antibodies to a subject in need thereof.
- Fibrotic Diseases: The patent defines a range of fibrotic diseases, encompassing conditions affecting various organs, such as the liver (e.g., idiopathic pulmonary fibrosis, liver fibrosis), lungs (e.g., pulmonary fibrosis), kidneys (e.g., kidney fibrosis), and skin (e.g., systemic sclerosis).
The scope extends to compositions containing these antibodies, pharmaceutical formulations, and uses of the antibodies in medical treatments. The patent's claims are structured to provide robust protection for Regeneron's specific therapeutic approach to fibrotic diseases through TGF-β1 inhibition.
What Are the Key Claims of U.S. Patent 11,786,455?
The patent contains multiple claims, organized into independent and dependent claims, which progressively narrow the scope of protection. Key claims include:
Independent Claim 1: This claim defines a specific antibody or an antigen-binding portion thereof. It specifies that the antibody or portion comprises:
- A heavy chain variable region comprising SEQ ID NO: 5.
- A light chain variable region comprising SEQ ID NO: 9.
This claim refers to specific amino acid sequences for the variable regions of the heavy and light chains, which define the antibody's antigen-binding site.
Independent Claim 14: This claim is directed to a method of inhibiting fibrosis in a subject. It involves administering a therapeutically effective amount of an antibody or an antigen-binding portion thereof, as defined in claim 1, to the subject. This claim directly links the claimed antibodies to their therapeutic application.
Independent Claim 15: This claim covers a pharmaceutical composition. It comprises an antibody or an antigen-binding portion thereof, as defined in claim 1, and a pharmaceutically acceptable carrier. This claim protects the formulation of the antibody for therapeutic use.
Dependent Claims: Numerous dependent claims further refine the scope. Examples include:
- Claims specifying humanized antibodies.
- Claims detailing particular IgG subclasses (e.g., IgG1).
- Claims defining binding affinities to TGF-β1 (e.g., dissociation constant values).
- Claims specifying the epitope on TGF-β1 to which the antibody binds.
- Claims enumerating specific fibrotic diseases to be treated, such as idiopathic pulmonary fibrosis, liver fibrosis, and kidney fibrosis.
The precise wording of these claims, particularly the SEQ ID numbers referencing specific amino acid sequences, provides a high degree of specificity and defines the boundaries of Regeneron's exclusive rights. Infringement would require the unauthorized making, using, selling, or importing of an antibody that falls within the parameters of these claims.
What is the Patent Landscape for TGF-β1 Inhibitors and Fibrotic Disease Therapeutics?
The patent landscape for TGF-β1 inhibitors and fibrotic disease therapeutics is dynamic and competitive, with numerous entities pursuing various strategies to address these challenging conditions. Regeneron's U.S. Patent 11,786,455 is one component within this broader ecosystem.
Key Players and Technologies:
- Small Molecule Inhibitors: Several companies have developed small molecule inhibitors targeting various components of the TGF-β signaling pathway, including TGF-β receptors or downstream effectors. Examples include drugs that have entered clinical trials for conditions like liver fibrosis and pulmonary fibrosis.
- Antibody-Based Therapies: Beyond Regeneron's antibody, other biopharmaceutical companies are developing monoclonal antibodies that neutralize TGF-β1 or other TGF-β isoforms. These antibodies aim to block the profibrotic effects of TGF-β.
- Gene Therapies and RNA Interference: Emerging strategies involve gene therapy or RNA interference (RNAi) to reduce the production of TGF-β or its downstream signaling molecules.
- Other Signaling Pathway Modulators: Research is also exploring targets upstream or downstream of TGF-β, as well as pathways that interact with TGF-β signaling to promote or resolve fibrosis.
Patent Activity:
The patent landscape is characterized by:
- Broad Composition of Matter Claims: Early patents often sought broad protection for novel compounds or antibodies targeting TGF-β or its receptors.
- Method of Use Claims: As specific therapeutic applications are discovered and validated, patents are filed for methods of treating particular fibrotic diseases using these agents.
- Epitope-Specific Claims: Similar to U.S. Patent 11,786,455, patents increasingly claim antibodies based on their binding to specific epitopes, offering more defined protection.
- Formulation and Delivery Patents: Patents also cover specific pharmaceutical formulations, dosage regimens, and delivery methods to improve efficacy and patient compliance.
- Combination Therapies: The complexity of fibrotic diseases leads to patent filings for combinations of TGF-β inhibitors with other therapeutic agents targeting different pathways.
Competitive Dynamics:
Companies actively engaged in this space include major pharmaceutical and biotechnology firms, as well as academic institutions. Key competitors in fibrotic disease research and TGF-β inhibition include, but are not limited to, companies like Gilead Sciences, Inc., Bristol Myers Squibb Company, Merck & Co., Inc., and various smaller biotech firms focused on specific fibrotic indications. The issuance of U.S. Patent 11,786,455 strengthens Regeneron's position, potentially creating barriers to entry for competitors developing similar TGF-β1 neutralizing antibodies with the same binding characteristics and therapeutic applications.
Challenges in Fibrotic Disease Therapeutics:
Despite significant research and patent activity, developing successful fibrotic disease therapies remains challenging due to:
- Complexity of Fibrosis: Fibrotic processes are often multifactorial, involving numerous cellular and molecular pathways, making single-target inhibition insufficient for some conditions.
- Timing of Intervention: The effectiveness of antifibrotic therapies may depend on the stage of the disease. Early intervention is often critical.
- Off-Target Effects: TGF-β has essential physiological roles beyond promoting fibrosis, including immune regulation and tissue repair. Inhibiting TGF-β broadly can lead to unwanted side effects. Patents like U.S. Patent 11,786,455 aim to mitigate this by targeting specific isoforms or neutralizing TGF-β in a manner that favors therapeutic benefit.
U.S. Patent 11,786,455 signifies Regeneron's proprietary position for a specific antibody targeting TGF-β1, contributing to the intricate intellectual property environment surrounding the development of novel fibrotic disease treatments.
Key Takeaways
- U.S. Patent 11,786,455 grants Regeneron Pharmaceuticals, Inc. exclusive rights to specific antibodies, including REGN5093 and REGN5093-1, designed to neutralize TGF-β1.
- The patent's claims are precisely defined by specific amino acid sequences of antibody variable regions and target binding to a particular epitope on TGF-β1.
- The patent covers methods of treating or preventing a range of fibrotic diseases, encompassing hepatic, pulmonary, and renal fibrosis.
- The patent landscape for fibrotic disease therapeutics is competitive, featuring small molecule inhibitors, antibody-based therapies, and emerging technologies like gene therapy.
- U.S. Patent 11,786,455 strengthens Regeneron's market position by providing protection for its distinct TGF-β1 inhibition strategy.
FAQs
-
What specific diseases are covered by the patent?
The patent covers a range of fibrotic diseases, including but not limited to idiopathic pulmonary fibrosis, liver fibrosis, and kidney fibrosis.
-
Does this patent prevent all TGF-β1 inhibitors from being developed?
No, this patent protects specific antibodies as defined by their amino acid sequences and epitope binding. Other TGF-β1 inhibitors, particularly those with different mechanisms of action or binding sites, may not be covered.
-
What are the identified antibodies in the patent?
The patent specifically identifies antibodies REGN5093 and REGN5093-1, characterized by specific heavy and light chain variable region sequences (SEQ ID NO: 5 and SEQ ID NO: 9, respectively).
-
What is the significance of the claimed epitope?
The claimed epitope is a specific region on the TGF-β1 protein that the antibody binds to. This specificity is crucial for defining the antibody's interaction and therapeutic effect, distinguishing it from other potential binders.
-
What is the duration of protection for U.S. Patent 11,786,455?
U.S. patents generally have a term of 20 years from the filing date, subject to maintenance fees. The specific expiry date would depend on the patent's filing date and any applicable extensions or adjustments.
Citations
[1] Regeneron Pharmaceuticals, Inc. (2023). Antibodies to TGF-β1 and Methods of Use. U.S. Patent 11,786,455. Retrieved from [USPTO Patent Full-Text and Image Database]
More… ↓
⤷ Start Trial
|
